

Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors: an analysis of the UK Biobank

Maxine Sun^{1,2,3}, Marie-Christyne Cyr^{1,2}, Johanna Sandoval^{1,2}, Louis-Philippe Lemieux Perreault^{1,2}, Lambert Busque^{3,4}, Jean-Claude Tardif^{1,3}, Marie-Pierre Dubé^{1,2,3}

¹Montreal Heart Institute, Montreal, Canada

²Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, Montreal, Canada

³Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Canada

⁴Hôpital Maisonneuve-Rosemont

Corresponding author:

Marie-Pierre Dubé, PhD

Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre

5000 Belanger Street, Montreal, QC, H1T 1C8 Canada

Tel: +514 376 3330; Fax: + 514 593 2521

Email: marie-pierre.dube@umontreal.ca

Disclosures/Conflicts of interest:

M-P.D. has received personal fees and reports minor equity interest in Dalcour Pharmaceuticals. M-P.D. has a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcour Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcour Pharmaceuticals, no royalties received; and a patent Methods for using low dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute.

J-C.T. reports research grants from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Novartis, Pfizer, and RegenXBio; honoraria from AstraZeneca, DalCor Pharmaceuticals, HLS Pharmaceuticals, Pendopharm and Pfizer; minor equity interest from Dalcour Pharmaceuticals; and authorship on a patent Methods for Treating or Preventing Cardiovascular Disorders and Lowering Risk of Cardiovascular Events issued to Dalcour Pharmaceuticals, no royalties received; a patent Genetic Markers for Predicting Responsiveness to Therapy with HDL-Raising or HDL Mimicking Agent issued to Dalcour Pharmaceuticals, no royalties received; a pending patent Early administration of low-dose colchicine after myocardial infarction, and a patent Methods for using low-dose colchicine after myocardial infarction, assigned to the Montreal Heart Institute (J-C.T. has waived his rights in the colchicine patents).

Other authors have nothing to declare.

Funding

M.S. was funded by a doctorate scholarship from the Fonds de Recherche du Québec - Santé (FRQS). M-P.D. and J-C.T. hold Canada Research Chairs. This project was funded in part by the Health Collaboration Acceleration Fund (FACS) from the Government of Quebec (J-C.T. principal investigator and M-P.D. co-principal investigator).

Acknowledgements

We thank the UK Biobank for providing the data under Application Number 20168.

1 **ABSTRACT**

2
3 Cancer survivors are at an increased risk of cardiovascular disease (CVD) compared to
4 the general population. Here, we evaluated the impact of somatic mosaic chromosomal
5 alterations (mCAs) on death of CVD causes, coronary artery disease (CAD) causes,
6 from cancer, and of any cause in patients with a cancer diagnosis within the UK Biobank
7 (n=48 919). mCAs were derived from DNA genotyping array intensity data and long-
8 range chromosomal phase inference from participants. Overall, 10 070 individuals
9 (20.6%) carried ≥ 1 mCA clone. In adjusted analyses, mCA was associated with an
10 increased risk of death of CAD causes (hazard ratio [HR]: 1.37, 95% confidence interval
11 [CI]: 1.09-1.71, $P=0.006$), from cancer (HR: 1.06, 95% CI: 1.00-1.11, $P=0.041$), and
12 death of any cause (HR: 1.07, 95% CI: 1.02-1.12, $P=0.005$). Among cancer survivors,
13 carriers of any mCA are at an increased risk of death of CAD causes and of any cause
14 as compared to non-carriers.

15
16 **Keywords:** clonal hematopoiesis, CHIP, mosaic chromosomal alterations,
17 cardiovascular mortality, UK Biobank

18

19

1 INTRODUCTION

2 The number of survivors of cancer is growing worldwide due to the ageing populations
3 and improvements in early cancer detection and treatment modalities.¹ It is estimated
4 that over 26 million people in the United States alone will be living with a history of
5 cancer by the year 2040.^{2,3} Among cancer survivors, a pressing clinical problem is their
6 increased predisposition to cardiovascular disease (CVD)^{4,5} and treatment-related
7 cardiac dysfunction^{6,7}. Currently, there are no guideline recommendations with respect
8 to CVD screening for patients with cancer, possibly stemming from the lack of CVD-
9 related markers that can better risk-stratify cancer patients beyond existing
10 cardiovascular risk factors for the general population.⁸ The identification and
11 development of biomarkers that can eventually be used towards a risk assessment tool
12 for the purpose of discriminating patients diagnosed with cancer who are at a higher risk
13 of CVD may be useful.⁸

14 Clonal Hematopoiesis (CH) refers to a population of cells derived from a mutated
15 multipotent stem/progenitor cell occurring in the context of aging.⁹ CH can be caused by
16 somatic mutation in driver genes¹⁰⁻¹⁴ called clonal hematopoiesis of indeterminate
17 potential (CHIP)¹⁵, or by somatic mosaic chromosomal alterations (mCA).¹⁶⁻²⁰
18 Previously, CHIP has been associated with a greater burden of atherosclerotic vessel
19 disease²¹, a higher risk of myocardial infarction^{22,23}, inflammatory response²⁴, and death
20 of any cause^{11,12}. The presence of CHIP has also been associated with treatment-
21 related adverse outcomes in cancer survivors.^{25,26}

22 Somatic mCAs correspond to large chromosomal gains, loss, or copy neutral losses of
23 heterozygosity which can affect autosomes or sexual chromosomes.²⁷ The most

1 prevalent mCA is the loss of the Y chromosome in aging men.²⁸ Mosaic loss of the Y
2 chromosome has been associated with all-cause mortality^{29,30}, Alzheimer's disease³¹,
3 autoimmune disease³², diabetes²⁹, and cardiovascular events³³.

4 Given the links between CH and CVD in the normal aging population, and the paucity of
5 data in cancer survivors, we sought to evaluate the impact of mCAs on the risk of death
6 from CVD causes, from cancer, and of any cause among cancer survivors at risk of CVD
7 by relying on DNA genotyping array intensity data and long-range chromosomal phase
8 information inferred from participants of the UK Biobank. Our hypothesis was that
9 carriers of any mCA would be at higher risk of death from CVD causes compared to
10 their mCA non-carriers.

11

1 **Results**

2 *Baseline characteristics and mCA prevalence*

3 Overall, 48 919 participants were diagnosed with bladder, larynx, corpus uteri, prostate,
4 rectal, breast, kidney, non-Hodgkin lymphoma, melanoma, or lung cancer within the UK
5 Biobank (**Table 1**). The mean age at study entry was 60 years old (median 62,
6 interquartile range [IQR]: 56-65). Forty-six percent (45.8%) were men and 39.6%
7 previously smoked.

8 The presence of at least one mCA clone was observed in 20.6% (10 070/48 919) of
9 patients (**Suppl. Materials, sFigure 1A**). Of those, 2 432 were autosomal carriers and 1
10 910 had mCA in $\geq 10\%$ of peripheral leukocytes, defined as an expanded mCA clone.
11 Whereas most carriers had only one mCA, 812 individuals carried ≥ 2 non-overlapping
12 mCAs. In general, those with mCA were older (median 64 vs. 61 years), where the
13 prevalence of mCA increased with increasing age categories: 4.8% among those aged
14 < 49 years old, 12.1% for those aged 50-59 years old, 26.4% for those aged 60-69 years
15 old, and 30.4% for those aged ≥ 70 years old (**Suppl. Materials, sFigure 1B**).
16 Expectedly, 73.6% of patients with mCA were men, likely because the majority of mCA
17 carriers was due to loss of the Y chromosome ($n=6\ 558$). In comparison, mCA due to
18 loss of the X chromosome was observed in 1 641 patients (16.3%). Amongst patients
19 older than 65 years old, the prevalence of mCA according to cancer types was the
20 lowest for breast cancer (14%) and the highest for larynx cancer (43%, **Suppl.**
21 **Materials, sFigure 1C**).

22 *mCA and the risk of death of CVD causes, coronary artery disease (CAD) causes, from*
23 *cancer, and any cause*

1 In adjusted Cox regression analyses, mCA was associated with an increased risk of
2 death of coronary artery disease (CAD) causes (hazard ratio [HR]: 1.37, 95%
3 confidence interval [CI]: 1.09-1.71, $P=0.006$), death from cancer (HR: 1.06, 95% CI:
4 1.00-1.11, $P=0.041$), and death of any cause (HR: 1.07, 95% CI: 1.02-1.12, $P=0.005$,
5 **Figure 1**). These effects were maintained after the additional adjustment for
6 hypertension and body-mass index in sensitivity analyses (**Suppl. Materials, sTable 1**).
7 Sub-analyses according to smoking status showed that mCAs were associated with
8 significantly higher risks of death of CVD causes (smoking-by-mCA $P_{\text{interaction}}=0.044$),
9 and death of any cause (smoking-by-mCA $P_{\text{interaction}}=0.011$), but not with death of CAD-
10 causes (smoking-by-mCA $P_{\text{interaction}}=0.50$) or with death from cancer (smoking-by-mCA
11 $P_{\text{interaction}}=0.266$, **Suppl. Materials, sTable 2**). In sub-analyses considering
12 chemotherapy, chemotherapy-by-mCA interaction terms were not significant for any of
13 the primary endpoints (all $P_{\text{interaction}}\geq 0.05$, **Suppl. Materials, sTable 3**).
14 Different types of mCAs had different effects on the study endpoints. Notably, autosomal
15 mCAs were associated with death of CVD causes (HR: 1.35, 95% CI: 1.04-1.75,
16 $P=0.023$), with death from cancer (HR: 1.14, 95% CI: 1.04-1.24, $P=0.004$), as well as
17 with death of any cause (HR: 1.14, 95% CI: 1.06, 1.24, $P<0.001$, **Suppl. Materials,**
18 **sTable 4**). mCA due to loss of the X chromosome was associated with death of CAD
19 causes (HR: 2.02, 95% CI: 1.16, 3.54, $P=0.013$, **Suppl. Materials, sTable 5**), and mCA
20 due to loss of the Y chromosome was associated with death of any cause (HR: 1.08,
21 95% CI: 1.02-1.14, $P=0.009$, **Suppl. Materials, sTable 6**). Expanded mCAs taken
22 individually had no statistically significant impact on the primary endpoints (**Suppl.**
23 **Materials, sTable 7**). When considering the study population of 479 435 participants
24 with, and without a history of any cancer, the interaction terms between cancer and

1 mCA were significant for death from cancer ($P_{\text{interaction}} < 0.001$) and death of any cause
2 ($P_{\text{interaction}} < 0.001$, **Suppl. Materials, sTable 8**). On the other hand, the interaction terms
3 between cancer status and mCA for death of CVD causes and CAD causes were not
4 statistically significant (**Suppl. Materials, sTable 8**).

5 *mCA and the risk of death of CVD causes, CAD causes, from cancer, and any cause*
6 *according to cancer site*

7 In multivariable analyses where the effect of mCA was assessed in subgroups according
8 to cancer type, we found that carriers of mCAs diagnosed with kidney cancer had an
9 increased risk of death of CVD causes (HR: 2.03, 95% CI: 1.11-3.72, $P=0.022$) and CAD
10 causes (HR: 3.57, 95% CI: 1.44-8.84, $P=0.006$, **Suppl. Materials, sTables 9 & 10**)
11 compared to their mCA non-carriers counterparts diagnosed with kidney cancer. Women
12 diagnosed with breast cancer who carried a mCA also had a higher risk of death of CAD
13 causes (HR: 2.46, 95% CI: 1.23-4.92, $P=0.011$). mCA had no significant impact on
14 deaths from cancer in either cancer type (**Suppl. Materials, sTable 11**). Women carriers
15 of mCA diagnosed with corpus uteri cancer had an increased risk of death of any cause
16 (HR: 1.35, 95% CI: 1.01-1.80, $P=0.042$, **Suppl. Materials, sTable 12**).

17 *mCA and the risk of incident CV endpoints (exploratory analyses)*

18 In the overall cohort of cancer survivors ($n=48\ 919$), carriers of mCA had a higher risk of
19 incident ST-elevation myocardial infarction (STEMI) (HR: 1.19, 95% CI: 1.03-1.37,
20 $P=0.022$) and peripheral vascular disease (HR: 1.17, 95% CI: 1.04-1.31, $P=0.007$,
21 **Figure 2**) than mCA non-carriers. Amongst those aged 65 years and above, carriers of
22 mCA showed a higher risk of incident STEMI (HR: 1.23, 95% CI: 1.02-1.49, $P=0.034$),
23 non-STEMI (HR: 1.20, 95% CI: 1.03-1.40, $P=0.020$), stable angina (HR: 1.20, 95% CI:
24 1.00-1.44, $P=0.047$), intracerebral hemorrhage (HR: 1.22, 95% CI: 1.01-1.48, $P=0.038$),

- 1 subarachnoid hemorrhage (HR: 1.23, 95% CI: 1.01-1.50, $P=0.040$), and peripheral
- 2 vascular disease (HR: 1.20, 95% CI: 1.03-1.39, $P=0.017$, **Suppl. Materials, sTable 13**).
- 3

1 **DISCUSSION**

2
3 Here, we assessed the impact of somatic mCAs, a subtype of CH, on the risks of death
4 of CVD causes, CAD causes, from cancer, and death of any cause focusing exclusively
5 on individuals diagnosed with one of 10 cancer types known to have the highest
6 reported rates of CVD deaths³⁴. First, we found that carriers of mCAs had an increased
7 risk of death of CAD causes, from cancer, and of any cause. Some of the associations
8 were more impactful in mCA subtypes, notably autosomal mCAs were associated with
9 the risk of death of CVD causes, mCA due to loss of the X chromosome was associated
10 with the risk of death of CAD causes, and mCA due loss of the Y chromosome was
11 associated with the risk of death of any causes.

12 Second, exploratory analyses suggest that carriers of mCAs were at higher risk of
13 incident STEMI and peripheral vascular disease; and for cancer survivors aged >65
14 years, at a higher risk of incident NSTEMI, stable angina, intracerebral hemorrhage, and
15 subarachnoid hemorrhage. In comparison, a previous mCA study focusing on MI and
16 stroke did not find any significant associations when focusing on carriers of expanded
17 mCAs, regardless of cancer status.²⁰ The current study suggests that any mCA carrier
18 status can be prognostic of several other CV phenotypes in cancer survivors. Previous
19 research looking at mutation driven CH have correlated mutations in *DNMT3A* and
20 *TET2* with chronic heart failure in patients with STEMI (n=485).³⁵ In another study
21 including approximately 50 000 samples with exome sequencing data, Zekavat et al.²⁶
22 found that carriers of CHIP mutations had higher risks of peripheral artery disease.

23 Third, when considering cancer survivors, it is possible that cancer-directed treatments
24 may have perpetuated the influence of mCA on outcomes.²⁵ However, our sub-analyses

1 which included a chemotherapy-by-mCA interaction term failed to reach statistical
2 significance, albeit a near 2-fold increased risk of death of CAD causes for mCA
3 carriers. Previous work have supported the hypothesis that chemotherapy may lead to
4 clonal expansion of mutations in apoptosis or DNA repair genes (*TP53*, *PPM1D*)^{25,36}, and
5 that CHIP mutations caused by these genes could worsen the risk of atherosclerosis²⁶. It
6 is possible that chemotherapy usage may not be well-captured in the current database.
7 Furthermore, without knowledge on tumor aggressiveness in the current database, it
8 was not possible to exclude the presence of a selection bias where carriers of mCAs
9 may be at a more advanced stage of the disease or have a more aggressive tumor
10 histology, which may make them more likely to undergo additional lines of
11 chemotherapy, which could have contributed to their risks of CVD. It will be critical to
12 evaluate whether cancer-directed treatments have an additive or synergistic influence
13 on mCAs. Further research will be needed to understand the impact of mCAs on CVD
14 outcomes following modern standards of care, such as treatment with immune-
15 checkpoint inhibitors. In that scenario, mCA carriers may benefit from an in-depth
16 preventive cardiology approach prior to treatment where multi-disciplinary cardio-
17 oncology care could mitigate such risks.

18 Fourth, we found that the effect of mCA on the risks of death of CVD and CAD causes,
19 as well as of death of any cause was specific to previous smokers. This upholds the
20 findings of a recent study which established strong causal associations between
21 smoking and mCAs, and postulated that smoking may contribute to the selection of
22 clones bearing somatic mutations.³⁷ Indeed, we found that cancer survivors who are
23 carriers of mCAs may face added risks if they were previous smokers. Additional work is

1 required to better evaluate how smoking habits can impact mCAs and the downstream
2 consequences of such mutations, especially in patients diagnosed with cancer.
3 Nevertheless, the generalizability of our findings may be limited as the influence of mCA
4 was not consistent across all examined cancer types. This was not entirely unexpected
5 given the heterogeneous biology of cancers included and distinct mechanisms of mCAs
6 with respect to these cancers and treatments that patients received. Even so, the
7 associations observed within this study may inform future studies focusing on the effect
8 of mCA and the risks of death from CVD causes for specific cancer types.
9 Our study has additional limitations. First, our study did not consider CHIP mutations.
10 While the association of CHIP mutations with CVD has been established, it has not been
11 formally tested in patients diagnosed exclusively with non-hematologic cancer. There is
12 reason to believe that carriers of CHIP mutations in addition to being diagnosed with
13 cancer may face higher risks of CVD. In addition, the synergistic effect of both mCA and
14 CHIP mutation carriers amongst cancer survivors will be of interest to explore in future
15 studies. Second, It has been established that detectable hematopoietic loss of the X and
16 Y chromosomes increase with age, with more age-related pathologies in older
17 individuals than in younger individuals.^{38,39} Unexpectedly, the association between the
18 mosaic loss of the Y chromosome and death of CVD causes was not significant in the
19 current analysis that focused on cancer survivors. The non-significant association may
20 have been related to mosaic loss of the Y chromosome definition used, where a larger
21 percentage threshold of blood cells lacking chromosome Y may be more relevant. For
22 example, a recent analysis found that regardless of their cancer status, men with mosaic
23 loss of the Y chromosome in 40% or more of leukocytes displayed a 31% increased risk
24 of dying from any disease related to the circulatory system based on survival data from

1 the UK Biobank.³⁹ In contrast, the relative risk per 1% increase of detectable loss of Y
2 chromosome and the risk of death from CVD causes was more subdued (HR: 1.0054,
3 $P=0.001$).³⁹ We did also note that mosaic loss of the Y chromosome was rather
4 impactful for cancer-specific mortality, which may be relevant in considering the
5 significant association found between loss of the Y chromosome and death of any
6 cause. Third, mCA status was evaluated only at study entry. Reasonably, clones
7 carrying a mCA may undergo rapid changes following various environmental exposures
8 (e.g. smoking, chemotherapy). Under this premise, serial measurements of mCA may
9 better help inform the dose-response effect of such factors and mCA. Finally, while
10 adjustment was made for chemotherapy and radiotherapy treatment, some individuals
11 may have undergone such treatments in the outpatient setting, which would not have
12 been properly captured using inpatient procedural codes.

13 In conclusion, our study showed that mCAs are associated with higher risks of death of
14 CAD causes among cancer survivors. mCAs were also associated with higher risks of
15 death from cancer and death of any cause. Notably, autosomal mCAs appeared to be
16 driving most of the observed associations. Future studies may focus on specific cancer
17 types and their treatments to better ascertain the effect of mCA on the risk of CVD and
18 evaluate if they constitute a useful biomarker in the management of cancer survivors.

19

20 **METHODS**

21 *Study samples*

22 The UK Biobank is a large population-based cohort that includes over 500,000
23 participants aged between 40-70 years old, recruited from 2006 to 2010.⁴⁰ Baseline
24 interviews regarding their medical history and environmental exposures were conducted

1 in the UK across 22 assessment centers where blood samples for genotyping were also
2 obtained and blood analysis performed. Additional health outcome data, including
3 diagnoses of cancer and CVD, have been linked via UK national registries and hospital
4 records managed by the NHS, and genome-wide genotyping of blood-derived DNA was
5 performed by the UK Biobank using 2 genotyping arrays sharing 95% of marker content:
6 Applied Biosystems UK BiLEVE Axiom Array and Applied Biosystems UK Biobank
7 Axiom Array, both by Affymetrix.⁴¹

8 *Determination of mosaic chromosomal alterations*

9 Previously, Loh et al.²⁰ identified mosaic chromosomal alteration in 487 409 genotyped
10 individuals. As previously described^{19,20}, mCAs were determined from genotype
11 intensities $\log_2 R$ ratio (LRR) and B-allele frequency (BAF) values, which were used to
12 estimate the total and relative allelic intensities, respectively. Re-phasing was conducted
13 using Eagle2⁴² and mCA calling was performed by leveraging long-range phase
14 information searching for allelic imbalances between maternal and paternal allelic
15 fractions across contiguous genomic segments. For the purpose of our study, mCA calls
16 were obtained from dataset Return 3094 from the UK Biobank application 19808.^{20,42}
17 From the genetic data of the UK Biobank, 479 435 individuals who passed the sample
18 quality control criteria, including genotypic-phenotypic sex concordance, and without first
19 or second-degree relatives in the dataset were considered (**Figure 3**). Of those, we
20 identified 48 919 participants with a diagnosis of cancer before or after the baseline
21 assessment visit based on the cancer register, using ICD-9 and ICD-10 diagnostic
22 codes for bladder, larynx, prostate, corpus uteri, rectum, breast, kidney, non-Hodgkin
23 lymphoma, melanoma of the skin, or lung cancer (**Suppl. Materials, sTable 14**). These

1 specific cancer types were selected based on a previous publication which identified the
2 top 10 cancer sites with the largest percentage of deaths attributed to CVD.³⁴

3 *Exposure and clinical outcomes*

4 The exposure of interest was the presence of a mCA of any type, which was classified
5 as ≥ 1 or none. mCAs were also categorized as autosomal mCAs, loss of the X
6 chromosome, loss of the Y chromosome, and expanded mCAs (defined as mCAs
7 present in at least 10% of peripheral leukocyte DNA indicative of clonal expansion⁴³).
8 The study primary endpoints consisted of death of CVD causes, death of CAD causes,
9 death from cancer, and death of any cause based on ICD-10 codes for primary cause of
10 death from the death register records (**Suppl. Materials, sTable 15**). For each endpoint,
11 the time to death was calculated from the date of the assessment visit at the time of
12 recruitment into the UK Biobank (baseline) if patients' cancer diagnosis occurred *before*
13 baseline, and alternatively, from the date of cancer diagnosis if the cancer diagnosis
14 occurred *after* baseline. The number of days between a patient's cancer diagnosis date
15 and baseline was recorded, and it was set as 0 if the cancer diagnosis occurred after
16 baseline. For individuals who were not deceased, the end of follow-up was the last date
17 of death registered based on participant's country of enrolment (i.e., 2021-03-30 for
18 England, 2021-03-23 for Scotland and 2021-03-16 for Wales).

19 Other exploratory endpoints included various incident CV phenotypes⁴⁴ recorded after
20 patients' cancer diagnosis date (**Suppl. Materials, sTable 15**). For these endpoints, the
21 time to the event (i.e., incident CV event of interest or death of CVD causes) was
22 calculated from the date of cancer diagnosis. For those who did not experience any
23 incident CV events, censor date was set to the date of death of non-CVD causes, or the
24 last hospitalization date known for each patient.

1 *Statistical analyses*

2 In our primary analyses focusing on the association between mCAs and death of CVD
3 causes, CAD causes, from cancer, and death of any cause, Cox proportional hazards
4 regression models were used, adjusting for age at baseline, sex, smoking status,
5 treatment with chemotherapy and/or radiotherapy, the number of days between cancer
6 diagnosis and date of baseline, and principal components for genetic ancestry (PC, 1-
7 10). An mCA-by-cancer status interaction term was also assessed with respect to each
8 of the primary endpoints in the overall population including individuals without any
9 history of cancer (n=479 435). We further examined the associations of mCA types
10 (autosomal mCAs, mosaic loss of the Y chromosome, mosaic loss of the X
11 chromosome, and expanded mCAs) on the primary endpoints of interest. Sensitivity
12 analyses considered the additional adjustment for hypertension and body mass index.
13 Cox regression models were also used for exploratory analyses of incident CV
14 phenotypes. Sub-group analyses were conducted according to cancer types, smoking
15 status, treatment with chemotherapy, and age at baseline dichotomized at 65 years. All
16 analyses were performed using the survival package in R (version 4.1.2, Bird Hippie). All
17 analytical and summary reports were produced with gtsummary (version 1.6.1).⁴⁵

Figure Legends

Table 1. Summary descriptives of patients with a cancer diagnosis according to mosaic chromosomal alterations status. mCA: mosaic chromosomal alteration; IQR: interquartile range; SD: standard deviation; CVD: cardiovascular disease; CAD: coronary artery disease

Figure 1. Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on death of cardiovascular disease causes, of coronary artery disease causes, from cancer, and death of any cause. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CAD: coronary artery disease, CI: confidence interval, CVD: cardiovascular disease, HR: hazard ratio, mCA: mosaic chromosomal alterations, Ref.: referent category (1.0)

Figure 2. Multivariable Cox regression models evaluating the effect of mosaic chromosomal alterations on incident cardiovascular phenotypes. All models are adjusted for age at baseline, sex, smoking status, chemotherapy, radiotherapy, number of days between the date of recruitment and the date of cancer diagnosis, and principal components 1 to 10. CVD: cardiovascular disease, CI: confidence interval, HR: hazard ratio, mCA: mosaic chromosomal alteration, MI: myocardial infarction, NSTEMI: non-ST-elevation myocardial infarction, STEMI: ST-elevation myocardial infarction, TIA: transient ischemic attack.

Figure 3. Visual representation of the study flow.

sFigure 1. Visual depiction of the proportion of patients with at least 1 mosaic chromosomal alteration in the overall cohort (A), of the proportion of patients with at least one mosaic chromosomal alteration stratified according to age groups (B), and of the proportion of patients with at least one mosaic chromosomal alteration stratified according to cancer types (C). mCA: mosaic chromosomal alteration.

References

- 1 Coleman, M. P. *et al.* EURO CARE-3 summary: cancer survival in Europe at the end of the 20th century. *Annals of oncology : official journal of the European Society for Medical Oncology* **14 Suppl 5**, v128-149, doi:10.1093/annonc/mdg756 (2003).
- 2 Bluethmann, S. M., Mariotto, A. B. & Rowland, J. H. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. *Cancer Epidemiology, Biomarkers & Prevention* **25**, 1029-1036, doi:10.1158/1055-9965.EPI-16-0133 (2016).
- 3 Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. *CA: A Cancer Journal for Clinicians* **66**, 7-30, doi:<https://doi.org/10.3322/caac.21332> (2016).
- 4 Armenian, S. H. *et al.* Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **34**, 1122-1130, doi:10.1200/jco.2015.64.0409 (2016).
- 5 Haugnes, H. S. *et al.* Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **28**, 4649-4657, doi:10.1200/jco.2010.29.9362 (2010).
- 6 Emery, J. *et al.* Management of common clinical problems experienced by survivors of cancer. *Lancet (London, England)* **399**, 1537-1550, doi:10.1016/s0140-6736(22)00242-2 (2022).
- 7 Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B. & Johnson, D. B. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. *The Lancet* **391**, 933, doi:10.1016/S0140-6736(18)30533-6 (2018).
- 8 Lamberg, M. *et al.* Next Generation Risk Markers in Preventive Cardio-oncology. *Current Atherosclerosis Reports*, doi:10.1007/s11883-022-01021-x (2022).
- 9 Khoury, J. D. *et al.* The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* **36**, 1703-1719, doi:10.1038/s41375-022-01613-1 (2022).
- 10 Busque, L. *et al.* Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. *Nat Genet* **44**, 1179-1181, doi:10.1038/ng.2413 (2012).
- 11 Jaiswal, S. *et al.* Age-related clonal hematopoiesis associated with adverse outcomes. *The New England journal of medicine* **371**, 2488-2498, doi:10.1056/NEJMoa1408617 (2014).
- 12 Genovese, G. *et al.* Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. *New England Journal of Medicine* **371**, 2477-2487, doi:10.1056/NEJMoa1409405 (2014).
- 13 Xie, M. *et al.* Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med* **20**, 1472-1478, doi:10.1038/nm.3733 (2014).
- 14 McKerrell, T. *et al.* Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. *Cell Rep* **10**, 1239-1245, doi:10.1016/j.celrep.2015.02.005 (2015).
- 15 Steensma, D. P. *et al.* Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. *Blood* **126**, 9-16, doi:10.1182/blood-2015-03-631747 (2015).
- 16 Laurie, C. C. *et al.* Detectable clonal mosaicism from birth to old age and its relationship to cancer. *Nat Genet* **44**, 642-650, doi:10.1038/ng.2271 (2012).

- 17 Jacobs, K. B. *et al.* Detectable clonal mosaicism and its relationship to aging and cancer. *Nat Genet* **44**, 651-658, doi:10.1038/ng.2270 (2012).
- 18 Forsberg, L. A. *et al.* Age-related somatic structural changes in the nuclear genome of human blood cells. *American journal of human genetics* **90**, 217-228, doi:10.1016/j.ajhg.2011.12.009 (2012).
- 19 Loh, P.-R. *et al.* Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. *Nature* **559**, 350-355, doi:10.1038/s41586-018-0321-x (2018).
- 20 Loh, P.-R., Genovese, G. & McCarroll, S. A. Monogenic and polygenic inheritance become instruments for clonal selection. *Nature* **584**, 136-141, doi:10.1038/s41586-020-2430-6 (2020).
- 21 Jaiswal, S. *et al.* Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. *The New England journal of medicine* **377**, 111-121, doi:10.1056/NEJMoa1701719 (2017).
- 22 Bick, A. G. *et al.* Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis. *Circulation* **141**, 124-131, doi:10.1161/circulationaha.119.044362 (2020).
- 23 Honigberg, M. C. *et al.* Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. *Circulation* **143**, 410-423, doi:10.1161/CIRCULATIONAHA.120.051775 (2021).
- 24 Busque, L. *et al.* High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. *Blood Advances* **4**, 2430-2438, doi:10.1182/bloodadvances.2019000770 (2020).
- 25 Coombs, C. C. *et al.* Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. *Cell stem cell* **21**, 374-382.e374, doi:10.1016/j.stem.2017.07.010 (2017).
- 26 Zekavat, S. M. *et al.* TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease. *medRxiv*, 2021.2008.2022.21262430, doi:10.1101/2021.08.22.21262430 (2022).
- 27 Lin, S. H. *et al.* Incident disease associations with mosaic chromosomal alterations on autosomes, X and Y chromosomes: insights from a phenome-wide association study in the UK Biobank. *Cell Biosci* **11**, 143, doi:10.1186/s13578-021-00651-z (2021).
- 28 Forsberg, L. A. *et al.* Mosaic loss of chromosome Y in leukocytes matters. *Nat Genet* **51**, 4-7, doi:10.1038/s41588-018-0267-9 (2019).
- 29 Lofffield, E. *et al.* Predictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank. *Scientific Reports* **8**, 12316, doi:10.1038/s41598-018-30759-1 (2018).
- 30 Forsberg, L. A. *et al.* Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. *Nature Genetics* **46**, 624-628, doi:10.1038/ng.2966 (2014).
- 31 Dumanski, J. P. *et al.* Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. *American journal of human genetics* **98**, 1208-1219, doi:10.1016/j.ajhg.2016.05.014 (2016).
- 32 Persani, L. *et al.* Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis. *Journal of autoimmunity* **38**, J193-196, doi:10.1016/j.jaut.2011.11.011 (2012).
- 33 Haitjema, S. *et al.* Loss of Y Chromosome in Blood Is Associated With Major Cardiovascular Events During Follow-Up in Men After Carotid Endarterectomy. *Circulation. Cardiovascular genetics* **10**, e001544, doi:10.1161/circgenetics.116.001544 (2017).

- 34 Sturgeon, K. M. *et al.* A population-based study of cardiovascular disease mortality risk in US cancer patients. *European Heart Journal* **40**, 3889-3897, doi:10.1093/eurheartj/ehz766 (2019).
- 35 Wang, S. *et al.* Prevalence and prognostic significance of DNMT3A- and TET2- clonal haematopoiesis-driver mutations in patients presenting with ST-segment elevation myocardial infarction. *EBioMedicine* **78**, 103964, doi:10.1016/j.ebiom.2022.103964 (2022).
- 36 Bolton, K. L. *et al.* Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nature Genetics* **52**, 1219-1226, doi:10.1038/s41588-020-00710-0 (2020).
- 37 Levin, M. G. *et al.* Genetics of smoking and risk of clonal hematopoiesis. *Scientific Reports* **12**, 7248, doi:10.1038/s41598-022-09604-z (2022).
- 38 Machiela, M. J. *et al.* Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. *Nature Communications* **7**, 11843, doi:10.1038/ncomms11843 (2016).
- 39 Sano, S. *et al.* Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality. *Science* **377**, 292-297, doi:doi:10.1126/science.abn3100 (2022).
- 40 Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine* **12**, e1001779, doi:10.1371/journal.pmed.1001779 (2015).
- 41 Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 42 Loh, P.-R. *et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nature Genetics* **48**, 1443-1448, doi:10.1038/ng.3679 (2016).
- 43 Zekavat, S. M. *et al.* Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. *Nature Medicine* **27**, 1012-1024, doi:10.1038/s41591-021-01371-0 (2021).
- 44 Wan, E. Y. F. *et al.* Blood Pressure and Risk of Cardiovascular Disease in UK Biobank. *Hypertension* **77**, 367-375, doi:10.1161/HYPERTENSIONAHA.120.16138 (2021).
- 45 Sjoberg DD, Whiting K, Curry M, Lavery JA & J, L. Reproducible summary tables with the gtsummary package. *The R Journal* **13**, 570-580 (2021).

Table 1. Summary descriptives of patients with a cancer diagnosis stratified according to mosaic chromosomal alteration status.

Characteristic	N	Overall, N = 48,919 ¹	No mCA, N = 38,849 ¹	Any mCA, N = 10,070 ¹	p-value ²
Age at bsl	48,919				<0.001
N		48,919	38,849	10,070	
N missing		0	0	0	
Mean (SD)		60 (7)	60 (7)	63 (5)	
Median (IQR)		62 (56, 65)	61 (55, 65)	64 (61, 67)	
Range		40, 71	40, 70	40, 71	
Men	48,919	22,403 (45.8%)	14,989 (38.6%)	7,414 (73.6%)	<0.001
Smoking status	48,624				<0.001
Never smoker		23,865 (49.1%)	19,888 (51.5%)	3,977 (39.7%)	
Previous smoker		19,274 (39.6%)	14,755 (38.2%)	4,519 (45.1%)	
Current smoker		5,485 (11.3%)	3,970 (10.3%)	1,515 (15.1%)	
Unknown		295	236	59	
Prevalent CVD	48,919	43,342 (88.6%)	34,805 (89.6%)	8,537 (84.8%)	<0.001
Bladder cancer	48,919	1,743 (3.6%)	1,191 (3.1%)	552 (5.5%)	<0.001
Larynx cancer	48,919	375 (0.8%)	245 (0.6%)	130 (1.3%)	<0.001


Characteristic	N	Overall, N = 48,919 ¹	No mCA, N = 38,849 ¹	Any mCA, N = 10,070 ¹	p-value ²
Corpus Uteri	48,919	2,331 (4.8%)	2,108 (5.4%)	223 (2.2%)	<0.001
Prostate cancer	48,919	13,274 (27.1%)	8,970 (23.1%)	4,304 (42.7%)	<0.001
Breast cancer	48,919	17,304 (35.4%)	15,678 (40.4%)	1,626 (16.1%)	<0.001
Rectal cancer	48,919	2,268 (4.6%)	1,731 (4.5%)	537 (5.3%)	<0.001
Kidney cancer	48,919	1,910 (3.9%)	1,472 (3.8%)	438 (4.3%)	0.010
Non-Hodgkin lymphoma	48,919	3,038 (6.2%)	2,189 (5.6%)	849 (8.4%)	<0.001
Melanoma	48,919	4,912 (10.0%)	4,031 (10.4%)	881 (8.7%)	<0.001
Lung cancer	48,919	4,215 (8.6%)	3,074 (7.9%)	1,141 (11.3%)	<0.001
Chemotherapy	48,919				<0.001
None		37,512 (76.7%)	29,610 (76.2%)	7,902 (78.5%)	
Yes		11,407 (23.3%)	9,239 (23.8%)	2,168 (21.5%)	
Radiotherapy	48,919				0.036
None		45,846 (93.7%)	36,454 (93.8%)	9,392 (93.3%)	
Yes		3,073 (6.3%)	2,395 (6.2%)	678 (6.7%)	
Prevalent hypertension	48,919	6,077 (12.4%)	4,569 (11.8%)	1,508 (15.0%)	<0.001
Autosomal mCA	48,919				<0.001

Characteristic	N	Overall, N = 48,919 ¹	No mCA, N = 38,849 ¹	Any mCA, N = 10,070 ¹	p-value ²
Ref.		46,487 (95.0%)	38,849 (100.0%)	7,638 (75.8%)	
Autosomal		2,432 (5.0%)	0 (0.0%)	2,432 (24.2%)	
Loss of X	48,919				<0.001
Ref.		47,278 (96.6%)	38,849 (100.0%)	8,429 (83.7%)	
Loss of X		1,641 (3.4%)	0 (0.0%)	1,641 (16.3%)	
Loss of Y	48,919				<0.001
Ref.		42,361 (86.6%)	38,849 (100.0%)	3,512 (34.9%)	
Loss of Y		6,558 (13.4%)	0 (0.0%)	6,558 (65.1%)	
Expanded mCA	48,919				<0.001
Ref.		47,009 (96.1%)	38,849 (100.0%)	8,160 (81.0%)	
Expanded mCA		1,910 (3.9%)	0 (0.0%)	1,910 (19.0%)	
Death of CVD causes	48,919	813 (1.7%)	550 (1.4%)	263 (2.6%)	<0.001
Death of CAD causes	48,919	368 (0.8%)	226 (0.6%)	142 (1.4%)	<0.001
Death from cancer	48,919	8,433 (17.2%)	6,254 (16.1%)	2,179 (21.6%)	<0.001
Death of any cause	48,919	10,632 (21.7%)	7,785 (20.0%)	2,847 (28.3%)	<0.001

¹ n (%)

² Wilcoxon rank sum test; Pearson's Chi-squared test

bsl.: baseline, CAD: coronary artery disease, CVD: cardiovascular disease, IQR: interquartile range, mCA: mosaic chromosomal alteration, Ref.: referent category, SD: standard deviation



UK Biobank
with genotyping data
(N = 488 377)

Genome-wide mCA
detection
(N = 479 435)

Top 10 cancers with
highest cardiovascular
death % (N = 48 919)

Exposure:
mCA (n = 10 070)
v.s.
no mCA (n = 38 849)

Primary endpoints:

1. Death of CVD causes
2. Death of CAD causes
3. Death from cancer
4. Death of any cause

Exploratory endpoints:

4. Incident CV phenotypes